Search Results | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Abstract 198: The T3R domain of thrombospondin-1 delays tumor growth and improves tumor response to chemotherapy by remodeling the tumor vasculature

Denise Pinessi, Andrea Resovi, Lavinia Morosi, Patrizia Borsotti, Alexander Berndt, Raffaella Giavazzi, Massimo Zucchetti, Giulia Taraboletti

Cancer Res (2019) 79 (13_Supplement): 198.

DOI: https://doi.org/10.1158/1538-7445.AM2019-198

Published: 01 July 2019

View article

Journal Articles

Abstract 3377: Bevacizumab-improved distribution of paclitaxel in ovarian cancer xenografts potentiates antitumor efficacy

Marta Cesca, Lavinia Morosi, Alexander Berndt, Ilaria Fuso Nerini, Alessandra Decio, Massimo Zucchetti, Raffaella Giavazzi

Cancer Res (2016) 76 (14_Supplement): 3377.

DOI: https://doi.org/10.1158/1538-7445.AM2016-3377

Published: 15 July 2016

View article

Journal Articles

Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response

Marta Cesca, Lavinia Morosi, Alexander Berndt, Ilaria Fuso Nerini, Roberta Frapolli, Petra Richter, Alessandra Decio, Olaf Dirsch, Edoardo Micotti, Silvia Giordano, Maurizio D'Incalci, Enrico Davoli, Massimo Zucchetti, Raffaella Giavazzi

Mol Cancer Ther (2016) 15 (1): 125–135.

DOI: https://doi.org/10.1158/1535-7163.MCT-15-0063

Published: 07 January 2016

View article

Includes: Supplementary data

Journal Articles

The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts

Ezia Bello, Giulia Taraboletti, Gennaro Colella, Massimo Zucchetti, Daniele Forestieri, Simonetta A. Licandro, Alexander Berndt, Petra Richter, Maurizio D'Incalci, Ennio Cavalletti, Raffaella Giavazzi, Gabriella Camboni, Giovanna Damia

Mol Cancer Ther (2013) 12 (2): 131–140.

DOI: https://doi.org/10.1158/1535-7163.MCT-12-0275-T

Published: 10 February 2013

View article

Includes: Supplementary data

Journal Articles

Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin–Positive Metastatic Human Melanoma Xenografts

Michele Moschetta, Francesca Pretto, Alexander Berndt, Kerstin Galler, Petra Richter, Andrea Bassi, Paolo Oliva, Edoardo Micotti, Giovanni Valbusa, Kathrin Schwager, Manuela Kaspar, Eveline Trachsel, Hartwig Kosmehl, Maria Rosa Bani, Dario Neri, Raffaella Giavazzi

Cancer Res (2012) 72 (7): 1814–1824.

DOI: https://doi.org/10.1158/0008-5472.CAN-11-1919

Published: 01 April 2012

View article

Includes: Supplementary data

Journal Articles

Abstract C192: Molecular mechanisms of antitumor activity of the combination of E-3810 and paclitaxel in MDA-MB-231 triple-negative breast xenograft.

Ennio Cavalletti, Gabriella Camboni, Pietro Spinelli, Gennaro Colella, Giovanna Damia, Ezia Bello, Alexander Berndt, Petra Richter

Mol Cancer Ther (2011) 10 (11_Supplement): C192.

DOI: https://doi.org/10.1158/1535-7163.TARG-11-C192

Published: 12 November 2011

View article

Journal Articles

Abstract 5164: Selectively enriched CD90/Thy-1-positive cells from peripheral blood allow discrimination of patients and further analysis on a single cell level

Kathleen Wagner, Alexander Berndt, Andreas Hochhaus, Joachim H. Clement

Cancer Res (2011) 71 (8_Supplement): 5164.

DOI: https://doi.org/10.1158/1538-7445.AM2011-5164

Published: 15 April 2011

View article

Journal Articles

Abstract 2574: Striking activity of E-3810 combined with paclitaxel and 5FU in the triple negative breast cancer model MDA-MB-231

Giovanna Damia, Ezia Bello, Gennaro Colella, Alexander Berndt, Maurizio D'Incalci, Ennio Cavalletti, Gabriella Camboni

Cancer Res (2011) 71 (8_Supplement): 2574.

DOI: https://doi.org/10.1158/1538-7445.AM2011-2574

Published: 15 April 2011

View article

Journal Articles

E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models

Ezia Bello, Gennaro Colella, Valentina Scarlato, Paolo Oliva, Alexander Berndt, Giovanni Valbusa, Sonia Colombo Serra, Maurizio D'Incalci, Ennio Cavalletti, Raffaella Giavazzi, Giovanna Damia, Gabriella Camboni

Cancer Res (2011) 71 (4): 1396–1405.

DOI: https://doi.org/10.1158/0008-5472.CAN-10-2700

Published: 14 February 2011

View article

Includes: Supplementary data

Journal Articles

Abstract 3297: CD90/Thy-1-positive cells in the peripheral blood of tumor patients co-express CD44

Kathleen Wagner, Alexander Berndt, Andreas Hochhaus, Joachim H. Clement

Cancer Res (2010) 70 (8_Supplement): 3297.

DOI: https://doi.org/10.1158/1538-7445.AM10-3297

Published: 15 April 2010

View article

Journal Articles

Abstract A262: Antiangiogenic proprieties of E‐3810, a new dual inhibitor of VEGF and FGF receptors

Raffaella Giavazzi, Paolo Oliva, Giulia Taraboletti, Alexander Berndt, Sonia Colombo, Giovanni Valbusa, Ennio Cavalletti, Roberta Cereda, Giovanna Damia, Gabriella Camboni

Mol Cancer Ther (2009) 8 (12_Supplement): A262.

DOI: https://doi.org/10.1158/1535-7163.TARG-09-A262

Published: 10 December 2009

View article

Journal Articles

The effect of vandetanib on tumor vasculature remodeling and paclitaxel uptake in a xenograft model of ovarian carcinoma

Marta Cesca, Roberta Frapolli, Ezia Bello, Alexander Berndt, Petra Richter, Anderson Ryan, Raffella Giavazzi

Cancer Res (2008) 68 (9_Supplement): 4762.

Published: 01 May 2008

View article

Journal Articles

Synergistic Therapeutic Effects of a Tumor Targeting Antibody Fragment, Fused to Interleukin 12 and to Tumor Necrosis Factor α

Cornelia Halin, Verena Gafner, Maria Elena Villani, Laura Borsi, Alexander Berndt, Hartwig Kosmehl, Luciano Zardi, Dario Neri

Cancer Res (2003) 63 (12): 3202–3210.

Published: 15 June 2003

View article

NARROW

Abstract 198: The T3R domain of thrombospondin-1 delays tumor growth and improves tumor response to chemotherapy by remodeling the tumor vasculature

Abstract 3377: Bevacizumab-improved distribution of paclitaxel in ovarian cancer xenografts potentiates antitumor efficacy

Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response

The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts

Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin–Positive Metastatic Human Melanoma Xenografts

Abstract C192: Molecular mechanisms of antitumor activity of the combination of E-3810 and paclitaxel in MDA-MB-231 triple-negative breast xenograft.

Abstract 5164: Selectively enriched CD90/Thy-1-positive cells from peripheral blood allow discrimination of patients and further analysis on a single cell level

Abstract 2574: Striking activity of E-3810 combined with paclitaxel and 5FU in the triple negative breast cancer model MDA-MB-231

E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models

Abstract 3297: CD90/Thy-1-positive cells in the peripheral blood of tumor patients co-express CD44

Abstract A262: Antiangiogenic proprieties of E‐3810, a new dual inhibitor of VEGF and FGF receptors

The effect of vandetanib on tumor vasculature remodeling and paclitaxel uptake in a xenograft model of ovarian carcinoma

Synergistic Therapeutic Effects of a Tumor Targeting Antibody Fragment, Fused to Interleukin 12 and to Tumor Necrosis Factor α

AACR Journals

AACR Journals

This Feature Is Available To Subscribers Only